Journal of Clinical Medicine (Aug 2023)

Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain

  • Carlos González-Juanatey,
  • Manuel Anguita-Sánchez,
  • Vivencio Barrios,
  • Iván Núñez-Gil,
  • Juan José Gómez-Doblas,
  • Xavier García-Moll,
  • Carlos Lafuente-Gormaz,
  • María Jesús Rollán-Gómez,
  • Vicente Peral-Disdier,
  • Luis Martínez-Dolz,
  • Miguel Rodríguez-Santamarta,
  • Xavier Viñolas-Prat,
  • Toni Soriano-Colomé,
  • Roberto Muñoz-Aguilera,
  • Ignacio Plaza,
  • Alejandro Curcio-Ruigómez,
  • Ernesto Orts-Soler,
  • Javier Segovia-Cubero,
  • Víctor Fanjul,
  • Judith Marín-Corral,
  • Ángel Cequier,
  • SAVANA Research Group

DOI
https://doi.org/10.3390/jcm12165218
Journal volume & issue
Vol. 12, no. 16
p. 5218

Abstract

Read online

Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) without myocardial infarction (MI) or stroke are at high risk for major cardiovascular events (MACEs). We aimed to provide real-world data on age-related clinical characteristics, treatment management, and incidence of major cardiovascular outcomes in T2DM-CAD patients in Spain from 2014 to 2018. We used EHRead® technology, which is based on natural language processing and machine learning, to extract unstructured clinical information from electronic health records (EHRs) from 12 hospitals. Of the 4072 included patients, 30.9% were younger than 65 years (66.3% male), 34.2% were aged 65–75 years (66.4% male), and 34.8% were older than 75 years (54.3% male). These older patients were more likely to have hypertension (OR 2.85), angina (OR 1.64), heart valve disease (OR 2.13), or peripheral vascular disease (OR 2.38) than those aged p p = 0.003) and ischemic stroke (HR 2.39; p < 0.001). In summary, patients with T2DM-CAD in routine clinical practice tend to be older, have more comorbidities, are more heavily treated, and have a higher risk of developing MACE than is commonly assumed from clinical trial data.

Keywords